Covid and monoclonals, according to the latest Aifa report there are 35,948 patients for whom, starting from 10 March, they have been authorized as an emergency in Italy. In absolute numbers it is the Veneto the Region with the greatest use of monoclonals with 6,327 patients treated, followed by Lazio with 5,346 patients and from Tuscany with 3,953, while in the last places there are the autonomous province of Bolzano, and Molise and the autonomous province of Trento rise, respectively at 69, 89 and 150 patients included in the register.
Prescriptions for monoclonal antibodies against Covid-19 in Italy drop. After a long growing trend, in the last 7 days monitored by the Italian drug agency Aifa, from 6 to 12 January, drug requests were 2,555 against 3,794 of the previous week, with a daily average down by 29.54%. The majority of treated patients (16,892) received the casirivimab-imdevimab combination, followed by the bamlanivimab-etesevimab mix (16,691), while prescriptions of sotrovimab continue to increase (1,542), which is believed to be effective against the Omicron variant of Sars-CoV- 2. The prescriptions of bamlanivimab alone are stopped at 823.
#Covid #monoclonals #regions